University Hospitals Seidman Cancer Center researchers have developed a tool that could identify metastatic prostate cancer ...

A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment ...

Prostate cancer is the second-leading cause of cancer death in American men. About 1 in 8 men will be diagnosed with prostate ...

A polygenic risk score was able to detect a high proportion of clinically significant prostate cancer. Cancer would not have been detected in 71.8% of patients with the use of PSA or MRI screening.

A new study is set to investigate how AI could significantly improve doctors’ decisions regarding prostate cancer treatment. While diagnostic methods for the disease have become safer and more precise ...

Can PSA derivatives reduce unnecessary prostate MRI after negative biopsy? Learn how simple markers may guide imaging ...

In this cohort study, a novel prognostic model was developed to estimate prostate cancer-specific mortality (PCSM) while ...

Thanks to early detection and aggressive treatment for prostate cancer, 97 percent of all men diagnosed with the disease will survive at least 5 years and nearly 80 percent will survive at least a ...

The UCLA trial is currently enrolling patients.

Investigators sought to evaluate changes in the estimated CV risk of men with prostate cancer after 6 months of hormone therapy using clinical tools established for the general population. A post-hoc ...

Advanced imaging, particularly PSMA PET scans, enhances detection of microscopic disease, allowing for more precise treatment ...

For men at the highest risk of prostate cancer as determined by a polygenic risk score, the percentage found to have clinically significant disease was higher than the percentage that would have been ...